Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: Results of an interim analysis of a non-interventional study

Onkologie

Volumn 36, Issue 3, 2013, Pages 95-100

  Bergmann, Lothar ^a   Goebell, Peter J ^b   Kube, Ulrich ^c   Kindler, Manfred ^d   Herrmann, Edwin ^e   Janssen, Jan ^f   Schmitz, Joerg ^g   Weikert, Steffen ^h   Steiner, Gabriel ⁱ   Jakob, Andreas ^j   Staehler, Michael D ^k   Steiner, Thomas ^l   Overkamp, Friedrich ^m   Albrecht, Michael ⁿ   Guderian, Gernot ⁿ   Doehn, Christian ^o  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c Private Practice for Urology   (Germany)

^d Private Practice   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f Private Practice for Oncology   (Germany)

^g St Johannes Hospital   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ Hospital Meiningen   (Germany)

^j Private Practice for Oncology   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l HELIOS KLINIKUM ERFURT   (Germany)

^m Day Clinic for Hematology and Oncology   (Germany)

ⁿ NOVARTIS PHARMA GMBH   (Germany)

^o Urologikum Luebeck   (Germany)

more..

Author keywords

Advanced cancer; Everolimus; Metastatic disease; Renal cell carcinoma; Sequential therapy; Sorafenib; Sunitinib

Indexed keywords

BEVACIZUMAB; CYTOKINE; EVEROLIMUS; INTERFERON; PAZOPANIB; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR; VINBLASTINE;

ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; NAUSEA; PAIN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PNEUMONIA; PRURITUS; STOMATITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; PROTEIN-TYROSINE KINASES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK ASSESSMENT; SIROLIMUS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875126397     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000348522     Document Type: Article

References (18)

1. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr: TSC2 regulates VEGF through mTOR-dependent and-independent pathways. Cancer Cell 2003;4:147-158.
2. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-127.
3. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A: Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-4265.
4. Novartis Pharmaceuticals Corporation: Afinitor® (everolimus) Tablets for Oral Administration. East Hanover, NJ, Novartis Pharmaceuticals Corporation, 2011.
5. National Comprehensive Cancer Network, Inc.: The NCCN Clinical Practice Guidelines in Oncology™ for Kidney Cancer V.2, 2012. 2012. www.nccn.org.
6. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC: EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398-406.
7. Novartis Europharm Limited: Afinitor Summary of Product Characteristics. West Sussex, UK, Novartis Europharm Ltd., September 2011.
8. Bergmann L, Kube U, Kindler M, Kopke T, Steiner G, Janssen J, Fries S, Goebell P, Jakob A, Steiner T, Staehler MD, Overkamp F, Albrecht M, Doehn C: A noninterventional study of everolimus in metastatic renal cell cancer after use of 1 VEGFr-TKI: results of a preplanned interim analysis of a prospective study. Presented at the 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011.
9. Di Lorenzo G., De Placido S, Buonerba C: Second-line treatment for renal cell cancer. Br J Cancer 2012;106:617-618.
10. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931-1939.
11. Pfizer Limited: Inlyta (1 mg film-coated tablets) Summary of Product Characteristics. Sandwich, UK, Pfizer Ltd., 2012.
12. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman K, Senico P, Niethammer A, Lu D, Hariharan S, Motzer R: Temsirolimus vs. sorafenib as second line therapy in metastatic renal cell carcinoma: phase 3 results from the INTORSECT trial. Presented at 37th Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria, September 28-October 2, 2012.
13. Angevin E, Lin C, Pande AU, Lopez JA, Gschwend J, Harzstark AL, Shi M, Anak O, Escudier BJ: A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: phase I results. J Clin Oncol 2010;28(15 suppl):abstr 3057.
14. Blesius A, Beuselinck B, Chevreau C, Ravaud A, Rolland F, Oudard S, Escudier B: Are TKIs still active in patients treated with TKI and everolimus? Experience from 36 patients treated in France in the RECORD 1 trial. Presented at 35th Annual Congress of the European Society for Medical Oncology, Milan, Italy, October 8-12, 2010.
15. Calvo E, Escudier B, Motzer RJ, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Ravaud A, Kim D, Panneerselvam A, Anak O, Figlin RA: Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 2012;48:333-339.
16. Seidel C, Fenner M, Reuter C, Merseburger AS, Ganser A, Grunwald V: Retrospective analyses of patient characteristics having predictive impact on survival under everolimus. Onkologie 2011;34:111-114.
17. Grunwald V, Karakiewics PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I: An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer 2012;48:324-332.
18. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP: A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009;115:2438-2446.